Suppr超能文献

使用组蛋白脱乙酰酶抑制剂进行子宫内膜癌化疗的临床前研究。

Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.

作者信息

Takai Noriyuki, Narahara Hisashi

机构信息

Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita 879-5593, Japan.

出版信息

Obstet Gynecol Int. 2010;2010:923824. doi: 10.1155/2010/923824. Epub 2010 Feb 4.

DOI:10.1155/2010/923824
PMID:20169171
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2821626/
Abstract

Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in endometrial cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discuss the biologic and therapeutic effects of HDAC inhibitors (HDACIs) in treating endometrial cancer. HDACIs were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in a variety of endometrial cancer cell lines. Furthermore, HDACIs were able to induce the accumulation of acetylated histones in the chromatin of the p21(WAF1) gene in human endometrial carcinoma cells. In xenograft models, some HDACIs have demonstrated antitumor activity with only few side effects. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating endometrial cancer, with a special focus on preclinical studies.

摘要

由于表观遗传改变被认为与子宫内膜癌中肿瘤抑制基因的抑制和肿瘤发生的促进有关，具有组蛋白去乙酰化酶（HDAC）抑制活性的新型化合物是一种有吸引力的治疗方法。在本综述中，我们讨论了HDAC抑制剂（HDACIs）在治疗子宫内膜癌中的生物学和治疗效果。HDACIs能够介导多种子宫内膜癌细胞系中细胞生长的抑制以及细胞周期停滞、凋亡和与恶性表型相关基因的表达。此外，HDACIs能够诱导人子宫内膜癌细胞中p21（WAF1）基因染色质中乙酰化组蛋白的积累。在异种移植模型中，一些HDACIs已显示出抗肿瘤活性且副作用很少。在本综述中，我们讨论了HDACIs在治疗子宫内膜癌中的生物学和治疗效果，特别关注临床前研究。

相似文献

1
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
Obstet Gynecol Int. 2010;2010:923824. doi: 10.1155/2010/923824. Epub 2010 Feb 4.
2
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
J Oncol. 2010;2010:458431. doi: 10.1155/2010/458431. Epub 2009 Dec 20.
3
Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Asian Pac J Cancer Prev. 2011;12(3):575-80.
4
Epigenetic therapy in human choriocarcinoma.
Cancers (Basel). 2010 Sep 10;2(3):1683-8. doi: 10.3390/cancers2031683.
5
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Curr Med Chem. 2007;14(24):2548-53. doi: 10.2174/092986707782023299.
6
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
Clin Cancer Res. 2004 Feb 1;10(3):1141-9. doi: 10.1158/1078-0432.ccr-03-0100.
7
Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
Hum Reprod. 2011 Sep;26(9):2486-98. doi: 10.1093/humrep/der203. Epub 2011 Jun 29.
8
Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Cancer. 2004 Dec 15;101(12):2760-70. doi: 10.1002/cncr.20709.
9
Autophagic and apoptotic effects of HDAC inhibitors on cancer cells.
J Biomed Biotechnol. 2011;2011:830260. doi: 10.1155/2011/830260. Epub 2011 May 18.
10
M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Gynecol Oncol. 2006 Apr;101(1):108-13. doi: 10.1016/j.ygyno.2005.09.044. Epub 2005 Nov 2.

引用本文的文献

1
The cGAS-STING pathway and female reproductive system diseases.
Front Immunol. 2024 Oct 9;15:1447719. doi: 10.3389/fimmu.2024.1447719. eCollection 2024.
2
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
Int J Mol Sci. 2024 Jan 20;25(2):1278. doi: 10.3390/ijms25021278.
3
The Role of Hyperthermic Intraperitoneal Chemotherapy in Uterine Cancer Therapy.
Int J Mol Sci. 2023 Aug 2;24(15):12353. doi: 10.3390/ijms241512353.
4
The Role of Peroxisome Proliferator-Activated Receptors in Endometrial Cancer.
Int J Mol Sci. 2023 May 24;24(11):9190. doi: 10.3390/ijms24119190.
5
Histone Deacetylase 3 Governs β-Estradiol-ERα-Involved Endometrial Tumorigenesis via Inhibition of STING Transcription.
Cancers (Basel). 2022 Sep 28;14(19):4718. doi: 10.3390/cancers14194718.
6
Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma.
Dis Markers. 2021 Nov 12;2021:7850688. doi: 10.1155/2021/7850688. eCollection 2021.
7
The Spectrum of Mutations of Homocystinuria in the MENA Region.
Genes (Basel). 2020 Mar 20;11(3):330. doi: 10.3390/genes11030330.
8
Epigenetic inhibitors target multiple stages of Plasmodium falciparum parasites.
Sci Rep. 2020 Feb 11;10(1):2355. doi: 10.1038/s41598-020-59298-4.
9
Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
Adv Biomed Res. 2019 Oct 31;8:63. doi: 10.4103/abr.abr_142_19. eCollection 2019.
10
Anticancer Activity of Natural Compounds from Plant and Marine Environment.
Int J Mol Sci. 2018 Nov 9;19(11):3533. doi: 10.3390/ijms19113533.

本文引用的文献

1
Pharmacotherapy of endometrial cancer.
Expert Opin Pharmacother. 2009 Aug;10(12):1939-51. doi: 10.1517/14656560903061291.
2
Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
Chem Biol Interact. 2009 May 15;179(2-3):169-77. doi: 10.1016/j.cbi.2008.11.011. Epub 2008 Nov 25.
3
The many roles of histone deacetylases in development and physiology: implications for disease and therapy.
Nat Rev Genet. 2009 Jan;10(1):32-42. doi: 10.1038/nrg2485.
4
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gynecol Oncol. 2008 May;109(2):182-6. doi: 10.1016/j.ygyno.2008.01.009. Epub 2008 Mar 4.
5
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Curr Med Chem. 2007;14(24):2548-53. doi: 10.2174/092986707782023299.
6
A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
Gynecol Oncol. 2008 Jan;108(1):27-33. doi: 10.1016/j.ygyno.2007.08.098. Epub 2007 Oct 24.
7
Development of histone deacetylase inhibitors for cancer treatment.
Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583.
8
Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.
Gynecol Oncol. 2007 May;105(2):493-500. doi: 10.1016/j.ygyno.2007.01.012. Epub 2007 Feb 15.
9
Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Int J Mol Med. 2007 Feb;19(2):301-8.
10
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Mol Cancer Ther. 2006 Nov;5(11):2767-76. doi: 10.1158/1535-7163.MCT-06-0209.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验